- Open Access
Active full-length DNA Aβ42 immunization in 3xTg-AD mice reduces not only amyloid deposition but also tau pathology
Alzheimer's Research & Therapy volume 10, Article number: 115 (2018)
Alzheimer’s disease (AD) is the most well-known and most common type of age-related dementia. Amyloid deposition and hyperphosphorylation of tau protein are both pathological hallmarks of AD. Using a triple-transgenic mouse model (3xTg-AD) that develops plaques and tangles in the brain similar to human AD, we provide evidence that active full-length DNA amyloid-β peptide 1–42 (Aβ42) trimer immunization leads to reduction of both amyloid and tau aggregation and accumulation.
Immune responses were monitored by enzyme-linked immunosorbent assay (ELISA) (antibody production) and enzyme-linked immunospot (cellular activation, cytokine production). Brains from 20-month-old 3x Tg-AD mice that had received DNA Aβ42 immunotherapy were compared with brains from age- and gender-matched transgenic Aβ42 peptide-immunized and control mice by histology, Western blot analysis, and ELISA. Protein kinase activation and kinase levels were studied in Western blots from mouse hemibrain lysates.
Quantitative ELISA showed a 40% reduction of Aβ42 peptide and a 25–50% reduction of total tau and different phosphorylated tau molecules in the DNA Aβ42 trimer-immunized 3xTg-AD mice compared with nonimmunized 3xTg-AD control animals. Plaque and Aβ peptide reductions in the brain were due to the anti-Aβ antibodies generated following the immunizations. Reductions of tau were likely due to indirect actions such as less Aβ in the brain resulting in less tau kinase activation.
The significance of these findings is that DNA Aβ42 trimer immunotherapy targets two major pathologies in AD—amyloid plaques and neurofibrillary tangles—in one vaccine without inducing inflammatory T-cell responses, which carry the danger of autoimmune inflammation, as found in a clinical trial using active Aβ42 peptide immunization in patients with AD (AN1792).
Immunotherapeutic approaches have high potential for successful treatment interventions in Alzheimer’s disease (AD). Following the lessons learned from the first anti-amyloid-β peptide 1–42 (anti-Aβ42) clinical trial (AN1792), in which patients with AD received an Aβ42 vaccine and QS-21 adjuvant, which led to encephalitis in 6% of the treated patients, a major focus is now on avoiding autoimmune inflammation [1,2,3]. Ongoing clinical trials are pursuing passive vaccination with mouse monoclonal antibodies (mAbs) or fully human antibodies against Aβ42 peptide epitopes to avoid complications from autoimmunity [4,5,6,7]. A recent study in which patients received passive immunotherapy with an mAb targeting oligomeric or prefibrillar Aβ42 reported positive results regarding amyloid reduction in the brain as well as improved cognitive measurements .
Besides amyloid accumulation, tau aggregation and spreading have been associated with progression of AD. In fact, increased tau levels showed high correlation with cognitive decline in patients with AD . Tau immunotherapy is being evaluated in various preclinical and clinical trials as well, using active immunizations with peptides from different parts of the tau protein or passive immunizations using polyclonal or mAbs [10,11,12,13,14,15]. Antitau antibodies have been shown to act inside and outside of neurons and to reduce tau hyperphosphorylation as well as pathogenic tau seeding [16,17,18,19,20].
We report, for the first time in an AD mouse model, that active DNA Aβ42 immunization into the skin targets two pathologies: amyloid-containing plaques and tau. DNA vaccination, in which not the antigen (peptide or protein) but the DNA encoding this peptide is administered, is an alternative route of vaccination. Genes encoded by the DNA are expressed within the skin, and the peptides are taken up by dendritic cells traveling to the regional lymph nodes and presenting the antigen to B and T cells . Immune responses to DNA or peptide immunization differ qualitatively. We have shown previously that full-length DNA Aβ42 trimer immunization is noninflammatory and induces a regulatory immune response [22,23,24,25]. DNA Aβ42 trimer immunization has been shown to be effective in removing amyloid from the brain in immunized double-transgenic mice (APPswe/PS1 [26,27,28]). In the present study, we used a triple-transgenic AD mouse model (3xTg-AD) that exhibits Aβ and tau pathologies characteristic of human AD [29, 30]. We found that immunotherapy with DNA Aβ42 trimer leads to reduction of Aβ40/Aβ42 peptides and amyloid plaques, and we show for the first time that DNA Aβ42 trimer immunization leads also to significant reduction of tau from the mouse brain.
3xTg-AD [B6;129-Tg(APPSwe,tauP301L)1Lfa Psen1tm1Mpm/Mmjax, MMRRC Stock No: 34830-JAX] mice had been purchased from the Mutant Mouse Research and Resource Center at The Jackson Laboratory and were bred and housed at the UT Southwestern Medical Center animal facility under conventional conditions. This mouse model had been developed by Oddo and colleagues [29, 30]. Animal use was approved by the UT Southwestern Medical Center Animal Research Committee, and animal research was conducted under the Animal Research: Reporting of In Vivo Experiments guidelines .
Cohorts of 3xTg-AD mice were immunized with a DNA Aβ42 trimer vaccine, Aβ42 peptide (rPeptide, Watskinville, GA, luciferase (Luc) control DNA, or left untreated as controls. This mouse model that had been developed by Oddo and colleagues develops plaque and tangle pathology [29, 30]. Cohort 1 consisted of 16 Tg female mice and 8 wild-type controls, and cohort 2 consisted of 34 Tg female mice. Parallel immunized groups of 3xTg-AD males (16 males in cohort 3, 15 males in cohort 4) showed no plaque pathologies at 18 and 20 months of age, so this study used females only. The mice were vaccinated at a total of 13 time points until 20 months of age for final analyses. Collected brains were cut in a sagittal plane. One hemibrain was frozen and used in enzyme-linked immunosorbent assays (ELISAs) and Western blots, and the other half was fixed for immunostaining with anti-Aβ and antitau antibodies.
Immunizations and collection of blood samples
Immunizations were started in 4-month-old mice in groups of four to eight mice (3xTg-AD and 129/SvJ wild-type controls) with three initial immunizations in biweekly intervals (Fig. 1) with a Gal4/DNA Aβ42 trimer double-plasmid system (4 μg of DNA/immunization, ratio of 3:1 DNA Aβ42 trimer responder plasmid/Gal4 activator plasmid) via intradermal injection using a Helios gene gun (Bio-Rad Laboratories, Hercules, CA, USA) or via intraperitoneal injections of Aβ42 peptide (100 μg of peptide/immunization) with Quil-A (Sigma-Aldrich, St. Louis, MO, USA) as adjuvant as previously described [22,23,24,25]. The immunizations were boosted in 6-week intervals until the mice were 18 or 20 months old (up to 13 immunizations) (Fig. 1a). Control mice received Luc DNA immunizations (group 1) or no treatment (naïve controls, group 2). Blood samples were collected at different time points throughout the study 10 days following the respective immunization time points.
IHC of mouse brains
Sagittal parallel sections of paraformaldehyde (PFA)-fixed female mouse brains were stained with antibodies specific for Aβ42 (6E10, BioLegend, San Diego, CA, USA; McSA1, MédiMabs, Montreal, QC, Canada; MOAB-2, MilliporeSigma, Billerica, MA, USA) to detect intraneuronal Aβ42 deposition and amyloid plaques in the hippocampus and cortex of the mice. To stain for tangle pathology, we used HT7, AT8, AT100, AT180, and AT270 (Thermo Fisher Scientific, Waltham, MA, USA) and T22 (MilliporeSigma); anti-tau antibodies pT231, pS214, and pS404 (Abcam, Cambridge, MA, USA); and Tyr18 (MédiMabs). NeuN antibodies (clone ABN78, MilliporeSigma; clone 1B7, Abcam) were used to stain neurons. Prior to the staining, sections were treated with heat-mediated antigen retrieval for all the tau antibodies or incubation in 70% formic acid for all the Aβ antibodies. After staining, tissues were scanned using a NanoZoomer digital pathology system and analyzed with NDP.view software (both from Hamamatsu Photonics, Shizuoka, Japan).
Positive antibody staining area quantification
The Aβ and tau immunoreactive areas were quantified using the “area measure” tool in ImageJ software (National Institutes of Health, Bethesda, MD, USA ). Immunostained sections (sagittal sections of mouse brain) were imaged with a 20× objective and were converted into 8-bit grayscale. The Analyze > Measure tool was used to measure the total area occupied by positive staining in each image. The total area was averaged for the sections per mouse group. Values are arbitrary units expressed as mean ± SEM per area.
Anti-Aβ42 antibody ELISA and cytokine enzyme-linked immunospot assays
ELISAs for antibody levels in mouse plasma were performed according to standard procedures. Cytokine concentrations from cell culture supernatants and enzyme-linked immunospot (ELISPOT) assays to determine frequencies of cytokine-secreting cells were performed according to standard procedures and as previously described using commercially available antibody sets for mouse interferon (IFN)-γ, interleukin (IL)-17, and IL-4 (eBioscience, San Diego, CA, USA) [23,24,25].
Aβ and tau ELISAs
For semiquantitative analyses of total Aβ42, Aβ40, and tau (total tau, pT231, pS396, pT181, and pS199) levels in the brain, standard ELISAs were used (Thermo Fisher Scientific). Frozen mouse hemibrains of female mice were homogenized with a Dounce homogenizer in 10 volumes (wet brain weight) of extraction buffer [1 mM Tris, 1 mM ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid (EGTA), 1 mM dithiothreitol (DTT), 10% sucrose, pH 7.5). Following homogenization, lysates were centrifuged at 26,000 × g for 15 min at 4 °C to clear the homogenate. The supernatant (Sup 1) was removed, and the pellet was resuspended in 1% Triton® X-100/1 mM Tris/1 mM EGTA/1 mM DTT/10% sucrose, pH 7.5. The solution was centrifuged at 188,000 × g for 60 min at 4 °C. The supernatant was removed and stored at − 80 °C (detergent-soluble supernatant). The pellet was washed, dried, and dissolved in 5 M guanidine (nonsoluble fraction). Lysates containing the detergent-soluble and -nonsoluble brain fractions were further diluted in homogenate assay buffer (0.2 g/L KCl, 0.2 g/L KH2PO4, 8.0 g/L NaCl, 1.15 g/L Na2HPO4, 5% bovine serum albumin [fraction V], 0.03% Tween® 20, 1× protease inhibitor cocktail, and 1× phosphatase inhibitor cocktail, pH 7.4). Further dilutions and ELISAs were performed according to the manufacturer’s instructions.
Western blot analysis
Soluble hemibrain lysate fractions from female mice were separated on 12% or 8–16% SDS-PAGE gels, transferred to nitrocellulose membranes (Thermo Fisher Scientific), and probed with the primary antibody overnight at 4 °C. The following antibodies were used: Tau12, 43D (BioLegend), HT7 (Thermo Fisher Scientific), anti-extracellular signal-regulated kinase 1/2 (anti-ERK1/2) and phosphorylated ERK1/2, mitogen-activated protein kinase kinase 1/2 (MEK1/2) and phosphorylated MEK1/2, GSK-3β, GSK-3α/β, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), β-actin (1:1000; Cell Signaling Technology, Danvers, MA, USA), tubulin β (1:1000; Bio-Rad Laboratories), and phosphorylated glycogen synthase kinase 3β (GSK3β) Y216 (1:1000; Abcam). After incubation with horseradish peroxidase-conjugated secondary antibodies (Thermo Fisher Scientific; SouthernBiotech, Birmingham, AL, USA), antibody binding was visualized with an enhanced chemiluminescence detection reagent (ProSignal ECL; Genesee Scientific, San Diego, CA, USA) and captured on a Syngene G:Box system using GeneSys software (Syngene USA, Frederick, MD, USA). Gray-level intensities (densitometries) were quantified using gel analysis in ImageJ software . For verification of similar total protein concentrations applied on the SDS-PAGE gels, filters were reprobed with housekeeping genes GAPDH, actin, and tubulin.
For statistical analysis (unpaired Student’s t test with two-tailed p values, nonparametric Mann-Whitney U test, parametric multiple comparisons one-way analysis of variance [ANOVA] and column statistics), Prism software version 6 for Windows (GraphPad Software, La Jolla, CA, USA) was used. p ≤ 0.05 was considered significant.
Humoral and cellular immune responses in Aβ42-immunized mice
In 20-month-old transgenic mice that had received 13 immunizations (Fig. 1a), antibody levels reached 69.88 ± 11.08 μg of anti-Aβ42 immunoglobulin G (IgG)/ml of plasma (63.77 ± 19.53 μg anti-Aβ42 IgG/ml plasma in group 2) after DNA Aβ42 immunization and 655.9 ± 9.58 μg/ml after Aβ42 peptide immunization (763.4 ± 11.88 μg anti-Aβ42 IgG/ml plasma in group 2). Similar antibody levels were found in parallel immunized 20-month-old wild-type control animals: 49.79 ± 6.35 μg/ml in DNA Aβ42-immunized mice and 659.7 ± 6.95 μg/ml in Aβ42 peptide-immunized mice (Fig. 1b). DNA Aβ42 trimer-immunized mice had high levels of IgG1 and IgG2b antibodies. The overall isotype composition was IgG1 = IgG2b > IgG2a/c (IgG1/IgG2a ratio of 1.61). Low levels of IgG2a/c antibodies were consistent with a noninflammatory Th2 immune response (Fig. 1c). All peptide-immunized mice had mixed isotype profiles with similar levels of IgG1, IgG2a/c, and IgG2b antibodies, indicative of a mixed Th1/Th2 immune response (Fig. 1d). This mixed profile was found at high plasma dilutions up to 1:20,000 (Fig. 1e).
ELISPOT assays from splenocyte cultures of 3xTg-AD mice and wild-type mice were performed to detect IFN-γ (Th1 cytokine), IL-17A (Th17 cytokine), and IL-4 (Th2 cytokine) upon Aβ42 peptide restimulation in the immunized mice. Although we found high numbers of IFN-γ- and IL-17-secreting cells in peptide-immunized mice, low numbers of cells secreting these proinflammatory cytokines were found in DNA-immunized mice. In peptide immunized 3xTg-AD mice, IFN-γ-secreting cells were detected with 8 ± 11.27 spots in medium control wells and more than 1000 spots in the Aβ42 peptide restimulated wells (p < 0.0001 by Mann-Whitney U test) (Fig. 1f). We counted 104.7 ± 47.9 spots in medium control wells of DNA Aβ42-immunized 3xTg-AD mice with no increase in peptide restimulated wells (92 ± 39.95 spots; p = 0.7428). A similar pattern was observed for IL-17-secreting cells with increased numbers in Aβ42 peptide-immunized mice: 227 ± 15.52 spots after peptide restimulation compared with 5.3 ± 4.04 spots in medium control wells (p < 0.0001 by Mann Whitney U test) and no significant increase in IL-17-secreting cells after peptide restimulation in DNA Aβ42-immunized mice (87.33 ± 30.6 spots in Aβ42 peptide-containing wells, 111.7 ± 24.58 spots in medium control wells; p = 0.3439) (Fig. 1g). For a peptide mix (Aβ10–26/Aβ17–31) containing the T-cell epitope of several mouse major histocompatibility complex haplotypes (H2b, H2k, H2d, H2s), similar results were obtained in the ELISPOT assays (Fig. 1f).
Histology showing amyloid reduction from brain
In the initial studies, we used male and female mice and found large differences in the pathology between sexes. Figure 2a–d shows sections of 18- and 20-month-old mice for comparison of Aβ42 pathology in females and males. In 20-month-old mice, large numbers of Aβ plaques were found in the subiculum of the hippocampus in female mice (Fig. 2a), whereas no plaques were found in the 20-month-old males (Fig. 2b). Also, for tau antibody staining (HT7, AT180) in parallel sections, much less pathology was found in male mice (data not shown), and therefore we continued immunotherapy in the following groups only in females. In 18-month-old mice, amyloid plaques were abundant in the female mice (Fig. 2c). In age-matched male mice, only a few neurons with intracellular Aβ42 staining were found, but no plaques (Fig. 2d).
Aβ42 immunotherapy led to a reduction of the number of amyloid plaques in the hippocampus of treated mice. In Fig. 2e–h, staining for NeuN, which stains neurons (red color), and an Aβ antibody (McSA1), which stains amyloid plaques (brown color) are shown for the hippocampal area for representative examples of the different mouse groups in one experimental cohort. The mAb McSA1 recognizes the N-terminal region of the human Aβ peptide (Aβ1–12). This epitope is present in β-C-terminal fragment and amyloid precursor protein (APP) as well, but McSA1 has been reported as highly specific for Aβ as opposed to APP or soluble APP following competition studies with these antigens [33, 34]. Figure 2e shows staining of the hippocampus subiculum of a 20-month-old 3xTg-AD control female mouse. Figure 2f shows this area stained for neurons and amyloid in a 20-month-old wild-type control mouse. A reduction of amyloid plaques was seen in all mice that had received Aβ immunotherapy. Representative sections are shown for one Aβ42 peptide-immunized mouse (Fig. 2g) and one DNA Aβ42-immunized 3xTg-AD mouse (Fig. 2h).
Immunohistological staining of plaques in the brains of these mice was subjected to the counting of plaques > 10 μm in corresponding 1-mm2 areas (subiculum/CA1) of 15 control mice (7 DNA Aβ42-immunized mice and 8 Aβ42 peptide-immunized mice) by two blinded experimenters. These analyses showed significantly reduced plaque numbers in the DNA Aβ42-immunized mice (p = 0.0238 by Student’s t test compared with control mice) and a nonsignificant reduction in the Aβ42 peptide-immunized mice (p = 0.6809). Also, the difference in plaque numbers between the DNA Aβ42- and peptide-immunized mice was significant (p = 0.0487) (Fig. 2i).
Histology showing reduction in levels of phospho-tau
The use of the 3xTg-AD mouse model allowed us to analyze a second pathology of human AD, which is the hyperphosphorylation of tau and development of neurofibrillary tangles. IHC of 3xTg-AD brain sections with different antibodies specific for tau molecules phosphorylated at specific residues (AT180, AT8, AT270, pT404, pS212, Tyr18) showed that Aβ42 immunotherapy also led to a significant reduction in the levels of tau phosphorylation. In Fig. 3a, the age progression for tau phosphorylation in the 3xTg-AD mouse model is shown. Brains from 2-, 4-, 7-, 9-, 12-, and 18-month-old mice (n = 4/group) were harvested, and PFA-fixed, paraffin-embedded sections were analyzed with the mAb AT180, which detects tau phosphorylated at residue T231. In the comparison of the staining pattern with brains from 18-month-old 3xTg-AD mice, which had received DNA Aβ42 immunizations, we observed that the AT180 staining intensity of the immunized 18-month-old mice appeared more like the staining intensity in brains from 7- or 9-month-old mice (Fig. 3b). Sections from four 18-month-old Luc immunized control mice, five 18-month-old DNA Aβ42-immunized mice, and six 18-month-old Aβ42 peptide-immunized mice were semiquantitatively analyzed with the area measure tool in ImageJ software. The results showed an about 40% reduction after DNA Aβ42 immunization and an approximately 20% reduction after Aβ42 peptide immunization (Fig. 3c). However, owing to high SDs and the small number of control animals, the results were not statistically significant.
Staining with the AT8 antibody specific for pS201/pT205, which is a late tau phosphorylation site , was less prominent in 18-month-old mice, but good staining was observed in 20-month-old mice, which showed reduction of AT8 staining in DNA Aβ42 trimer-immunized mice. Figure 3d shows that AT8-positive neurons were detected in the hippocampus of 20-month-old 3xTg-AD control mice (sections from two mice). Two representative sections from the Aβ42 peptide-immunized 20-month-old 3xTg-AD mice are shown in Fig. 3e. The brains showed fewer AT8-positive neurons than in the control animals. Much less staining was found in DNA Aβ42 trimer-immunized mice. Figure 3 shows the respective brain sections of the hippocampus from two mice (insets show higher magnification of subiculum in Fig. 3f).
The histological data indicating a possible reduction of tau in the Aβ42-immunized mice led to further substantiation of this finding by Western blot analysis and a panel of commercially available tau ELISAs that allowed testing for statistical significance of reduction of different tau phosphorylation patterns.
Western blot analysis of total tau
The reduction of tau in mice that had received Aβ42 immunotherapy was further analyzed using Western blotting of the brain lysates. In the comparison of total tau detected with the mAb Tau12, it was found that both immunotherapies led to a reduction in tau. The reduction was not significant in Aβ42 peptide-immunized mice and was higher and significant in DNA Aβ42-immunized mice (p values of 0.0302, 0.0142, and 0.0023 from three independently performed Western blot analyses with detergent-soluble brain lysates). Figure 3g and h shows the results of one of these experiments (Western blot and ImageJ analysis of gray-level intensities of the bands, respectively). Total tau and phosphorylated tau were further analyzed by Western blotting, and the results are shown in Fig. 4. All band intensities were normalized to band intensities found in the reprobing of the Western blots with antibodies to housekeeping proteins. In the detergent-soluble fractions, tau detected with the mAb Tau12 was significantly reduced in brain lysates from DNA Aβ42-immunized mice (p = 0.0059 by Student’s unpaired t test) (Fig. 4a). The intensity of the Western blot band reactive to the mAb AT8 was only slightly reduced in DNA Aβ42-immunized mice (p = 0.3224, nonsignificant). The AT8-reactive protein band was found at higher molecular weight (about 65 kDa), which might correspond to the 64 kDa tau, a Tris-buffered saline-extractable hyperphosphorylated tau species described in the rTg4510 mouse brain (Fig. 4a, middle panel) . In Fig. 4b, two different total human tau antibodies, 43D and HT7, were directly compared in parallel-run SDS-PAGE. Significant reductions of tau were found in the brain samples from DNA Aβ42-immunized mice (HT7 antibody, p = 0.0152; 43D antibody, p = 0.0138).
These results are consistent with the ELISA results described in the “Quantification of tau in ELISAs” section below. Although the reductions in the detergent-soluble brain lysate fractions were obvious but statistically not significant, reductions in the nonsoluble brain lysates were highly significant. However, the nonsoluble fractions could not be tested, owing to the extraction method used with 5 M guanidine for the solubilization of the pellet. These samples are not compatible with SDS-PAGE. In future mouse cohorts, we will use a different extraction protocol allowing the nonsoluble brain lysate fractions to be analyzed in Western blots (SDS-PAGE).
Quantification of Aβx-42 and Aβx-40 in ELISAs
After analysis of brain histology as shown in Fig. 2, ELISAs were used for semiquantitative analyses of reduction of Aβx-40 and Aβx-42 peptides in DNA Aβ42 trimer- and Aβ42 peptide-immunized female 3xTg-AD mice. An increase of Aβ42 and Aβ40 peptides in brains from 3xTg-AD mice with age is shown in Fig. 5a. ELISAs were also used to quantify the reduction of Aβx-40 and Aβx-42 peptides due to DNA Aβ42 trimer and Aβ42 peptide immunization (Fig. 5b and c). Statistical significance for reduction of Aβ42 and Aβ40 was reached in the comparison of DNA Aβ42 trimer-immunized mice (n = 7, blue bars) compared with control animals (n = 14, black bars) in the nonsoluble fractions (p = 0.0461, Mann-Whitney U test, for Aβx-42; p = 0.0125 for Aβx-40). These reductions were nonsignificant in the one-way ANOVA (Fig. 5b). In the soluble brain lysate fractions, a reduction of both Aβ peptides was highly significant (p < 0.0008, Mann-Whitney U test; p = 0.0123, one-way-ANOVA, for Aβx-42; p = 0.0017, Mann-Whitney U test; p = 0.0028, one-way ANOVA for Aβx-40) (Fig. 5c) in DNA Aβ42-immunized mice. Aβx-42 peptides were also reduced in brains from Aβ42 peptide-immunized 3xTg-AD mice in the nonsoluble lysate and detergent-soluble lysates, but levels did not reach statistical significance (p = 0.2766 for nonsoluble Aβx-42, p = 0.0815 for soluble Aβx-42). Much less removal was found for Aβx-40 peptides in brains from Aβ42 peptide-immunized mice (Fig. 5b and c, yellow bars, right-hand graphs).
Quantification of tau in ELISAs
Histological analyses of the mouse brains with tau antibodies AT180 and AT8 (early and late tau phosphorylation) showed reduced staining in the immunized mice (Fig. 3). ELISAs were used for detection of total tau, pT231 tau, p396 tau, pT181 tau, and pS199 tau in the semiquantitative analyses of tau reduction in DNA Aβ42 trimer- and Aβ42 peptide-immunized 3xTg-AD mice. Tau was reduced in both mouse groups, which had received Aβ42 immunotherapy or DNA or peptide vaccine (Fig. 6a–e, Table 1). However, statistical significance was reached only in the DNA Aβ42 trimer-immunized mice (Table 1).
High levels of tau protein were found in the detergent soluble fractions: 1.235 × 105 ± 0.556 × 105 pg/ml brain lysate in the 20-month-old female 3xTg-AD control mice (n = 14), with small reductions in the mouse groups that had received Aβ42 immunotherapy (1.201 × 105 ± 0.44 × 105 pg/mg in the peptide-immunized mice [p = 0.9754, n = 9], and 0.928 × 105 ± 0.324 × 105 pg/mg [p = 0.1285] in DNA-immunized mice [n = 7]). Higher reductions of total tau were found in the nonsoluble brain lysate fractions: control mice had mean values of 7.322 × 105 ± 3.301 × 105 pg/mg; Aβ42 peptide-immunized mice had levels of 6.879 × 105 ± 3.153 × 105 pg/mg brain weight (p = 0.8446); and DNA Aβ42 trimer-immunized mice had significantly reduced levels of 3.793 × 105 ± 1.096 × 106 pg/mg brain weight of total human tau (p = 0.0411, one-way ANOVA) (Fig. 6a).
pT231 tau reached mean values of 1793 ± 490.3 U/mg brain weight in the detergent-soluble brain lysate fractions of 3xTg-AD control mice, 1454 ± 390.6 U/mg in Aβ42 peptide-immunized mice, and 1199 ± 221.5 U/mg in DNA Aβ42 trimer-immunized mice. Although the reduction in the peptide-immunized mice was not significant (p = 0.4767), the reduction in DNA-immunized mice was highly significant (p = 0.0091). In the nonsoluble brain fractions, a mean value of 1.296 × 105 ± 0.282 × 105 U/mg pT231 tau was found for control mice, 1.313 ± 0.338 × 105 U/mg was found in peptide-immunized mice, and 0.809 × 105 ± 0.192 × 105 U/mg was found in DNA-immunized mice (Fig. 6b). Thus, Aβ immunotherapy reduced the nonsoluble pT231 only in DNA Aβ42 trimer-immunized mice (p = 0.0017).
pS396 tau was slightly reduced in the detergent-soluble fraction for DNA Aβ42 trimer- and Aβ42 peptide-immunized female mice compared with 3xTg-AD female control mice (889.2 ± 273.2 pg/mg, 1264 ± 389.1 pg/mg, and 1441 ± 566 pg/mg, respectively; p = ns by one-way ANOVA). pS396 was significantly reduced in DNA Aβ42 trimer-immunized mice in the nonsoluble fractions with mean levels of 0.631 × 105 ± 0.121 × 105 pg/mg (p = 0.0007) compared with 1.136 × 105 ± 0.272 × 105 pg/mg in the 3xTg-AD control mice (Fig. 6c).
For pT181 tau, mean levels of 3.869 × 104± 1.774 × 104 pg/mg in the detergent-soluble brain lysates of 3xTg-AD control mice were reduced to 3.098 × 104 ± 0.99 × 104 pg/mg in Aβ42 peptide-immunized mice (p = 0.3686) and to 1.969 × 104 ± 0.507 × 104 pg/mg in DNA Aβ42 trimer-immunized mice (p = 0.0198). In the nonsoluble brain fractions, a level of 1.876 × 105 ± 0.591 × 105 pg/mg was measured for female 3xTg-AD control mice, which was reduced to 1.672 × 105 ± 0.661 × 105 pg/mg (p = 0.5123) in Aβ42 peptide-immunized mice and to 0.911 × 105 ± 0.248 × 105 pg/mg (p = 0.002, one-way ANOVA) in DNA Aβ42 trimer-immunized 3xTg-AD mice (Fig. 6d).
pS199 tau was also reduced after DNA Aβ42 immunotherapy: 20-month-old 3xTg-AD control mice had a mean 5341 ± 1208 pg/mg wet brain weight in the detergent-soluble fractions, and DNA Aβ42 trimer-immunized mice had a reduced level of 3227 ± 730.5 pg/mg wet brain weight (p = 0.0012). Aβ42 peptide-immunized mice showed no reduction (5094 ± 1246 pg/mg, p = 0.5995). Significant differences were present in the nonsoluble brain lysate fractions between female control and DNA Aβ42 trimer-immunized mice with mean levels of 2.69 × 105 ± 5.46 × 104 pg/mg in control mice and 1.58 × 105 ± 2.32 × 104 pg/mg in DNA-immunized mice (p = 0.0007) (Fig. 6e, Table 1). In peptide-immunized mice the reduction was not significant, with 2.34 × 105 ± 6.86 × 104 pg pS199/mg (p = 0.2496).
In comparison of the two Aβ immunotherapies, a better reduction with high significance for phosphorylated tau molecules was found in DNA Aβ42 trimer-immunized mice. Percentages of reduction were calculated for the groups, and the results are shown in Table 1. A greater than 20% higher reduction was found in the detergent-soluble brain fractions of DNA-immunized mice for pT181 and pS396. This was statistically significant in the comparison of DNA- and peptide-immunized mice for pS396 (p < 0.0311) (Table 1). For the nonsoluble brain fractions, 12–25% higher reductions were found in lysates from DNA Aβ42 trimer-immunized mice for total tau, pT231, pT181, and pS396. These values were statistically significant for the comparisons with the age- and gender-matched control mice (Fig. 6) and also in the comparison between the differently immunized groups of mice (Table 1).
Analyses of kinase variations
Western blot analyses were performed to detect whether different enzymatic kinase patterns could be found in brains from immunized mice. Significantly reduced levels of phosphorylated MEK (MAP2K), and phosphorylated ERK1/2 (p44/p42 mitogen-activated protein kinase [MAPK]), as well as reduced levels for the activated form of GSK3β (Y216), were found in brains from DNA-immunized mice. Figure 7 shows the detection MEK1/2 and phospho-MEK1/2 (Fig. 7a), as well as ERK1/2 and phosphorylated ERK1/2 (Fig. 7b), in brain lysates from seven DNA Aβ42-immunized mice compared with seven age- and gender-matched 3xTg-AD control mice and two 20-month-old wild-type mice.
Results from the semiquantitative analysis of gray-level intensities (ImageJ software) are depicted in Fig. 8. Reductions in protein levels of phospho-MEK1/2 (Fig. 8a), total ERK1/2, and phospho-ERK1/2 (Fig. 8b) in DNA Aβ42-immunized mice were significant (p values of 0.0379, 0.0006, and 0.0087, respectively, by Mann-Whitney U test). Significant reductions were also found for protein levels of activated GSK3β (p = 0.0006) (Fig. 8c). These data were further normalized against the protein levels of total MEK1/2, total ERK1/2, and total GSKα/β for each of the bands individually to compensate for the possibility of different overall protein levels for the tested enzymes in the brain lysates and shown as a percentage of protein (percentage of phosphorylated MEK, ERK, and GSKα/β). The percentage difference for phospho-MEK1/2 was highly significant between control and DNA Aβ42-immunized mice (p = 0.0031). In the comparison of phosho-ERK1/2 with total ERK1/2 in the DNA Aβ42-immunized mice, the reduction was not significant, because these mice already had less total ERK1/2. The percentage reduction of phospho-GSK3β (Y216) in the DNA Aβ42-immunized mice was highly significant (p = 0.006). No differences in protein levels between the mouse groups were observed for the proteins MEK1/2 (Fig. 7a), GSK3α/β (Fig. 7c), and the housekeeping protein β-tubulin (Fig. 7d). Of note, a blot with GSK3α/β is shown in the comparison for activated GSK3β because it appears that there is weak cross-reactivity of this specific antibody with both GSK3 bands (Fig. 7c, lower panel), but differences were seen only for the strong reactivity with GSK3β phosphorylated at residue Y216 (46 kD band). Only this activated form of GSK3β is described and discussed. No significant differences were found for total GSK3β protein levels in brain lysates from control and immunized mice (data not shown).
DNA Aβ42 immunotherapy results in significant reductions in Aβ42 peptide and plaque load in brains of the 3xTg-AD mouse model at 20 months of age, consistent with our previous results in double-transgenic mice [26, 27]. New findings shown with this vaccine for the first time were significant reductions of total tau and phosphorylated tau in brains of mice that had received active DNA Aβ42 trimer immunizations. This finding was confirmed by histology, Western blot analysis, and ELISA. Despite the 10× levels of anti-Aβ antibodies in peptide-immunized mice, peptide immunization was less efficacious, which is indicative of different Aβ species detected and removed by the antibodies generated following DNA Aβ42 immunization (e.g., Aβ oligomers). In fact, this was highly consistent throughout the study with more Aβ and more tau removed in DNA Aβ42 trimer-immunized mice than in Aβ42 peptide-immunized mice in all three assay systems used (immunohistology, Western blotting, ELISA). We had previously shown that the expression of the DNA Aβ42 trimer vaccine in skin shows production of Aβ oligomers . We had also previously shown that the epitope specificity of antibodies produced after DNA Aβ42 immunization differs from the Aβ1–15 B-cell epitope specificity and shows a wide reactivity with epitopes across the Aβ1–42 peptide [38,39,40]. Aβ oligomers in particular activate tau kinases, leading to hyperphosphorylation, and Aβ oligomers are also strong activators for cellular caspases, leading to tau cleavage and tau aggregation. Hyperphosphorylated tau and truncated tau are both prone to self-aggregation and tau accumulation in neurons, and phosphorylation of specific residues in tau (e.g., S422) are important for caspase-mediated cleavage. Thus, less tau phosphorylation leads to less tau truncation via caspase-mediated cleavage and therefore reduces tau aggregation and total tau levels, explaining why Aβ42 immunization and reduction of Aβ42 peptides in brain led also to reduction of total tau [41,42,43,44,45,46,47,48,49].
DNA Aβ42 immunotherapy led to a noninflammatory immune response with no T-cell proliferation and no inflammatory cytokines produced during the cellular immune responses in the 3xTg-AD mouse model, similar to the immune responses we had found in the wild-type mouse model [22,23,24,25]. Although in the Balb/c wild-type mouse strain IgG1 was a dominant IgG antibody isotype in the humoral immune response , other mouse strains showed also a strong anti-Aβ42 IgG2b antibody production similar to the one found in the 3xTg-AD mouse used in the present study (unpublished data). Aβ42 peptide immunization led to a mixed immune response with high levels of all antibody isotypes, including IgG2a/c, and high levels of inflammatory cytokines in AD mouse models and wild-type mice [22,23,24,25, 28]. In a prime boost study, in which the immune response was first primed with Aβ42 peptide immunizations and then boosted with DNA Aβ42 immunizations in wild-type mice, we found that even though the anti-Aβ42 antibody isotype profile had high levels of “inflammatory” IgG2a/c antibodies, no inflammatory cytokines were detected in the cellular in vitro assays, providing evidence that the DNA immunization resulted in the downregulation of inflammatory cellular responses . Antibody isotypes strongly influence the therapeutic effect of a treatment or vaccine because the different antibody isotypes have different effector functions (complement binding, Fc receptor binding). In AD immunotherapy, microglial activation is thought to help remove excess Aβ from the brain, so that FcR binding is not a negative feature of the antibody per se. Furthermore, the epitope detected by the respective antibody pool is crucial for removal of amyloid from the brain [51,52,53]. Thus, the multivalent nature of the humoral immune response following DNA Aβ42 immunization is beneficial in many aspects.
To address how either DNA Aβ42 or Aβ peptide vaccinations can cause both Aβ and tau reduction, we investigated a number of kinases involved in tau phosphorylation that had also been shown to be activated by Aβ42 peptides and in particular Aβ42 oligomers [54,55,56]. We were able to show differences for the activated/phosphorylated kinases MEK1/2, p40/p42 MAPK1 and MAPK2 (ERK1/2), and GSK-3β in brain protein lysates from female DNA Aβ42-immunized mice compared with the age- and gender (female)-matched 3xTg-AD control mice, supportive of the assumption that a higher removal of Aβ oligomers after DNA Aβ42 trimer immunization has significant effects on tau pathology via changes on cellular kinases. ERK1 and ERK2 are both highly expressed in the brain, and it had been shown in vitro that ERK2 is capable of phosphorylating a large number of residues in tau. Activation of the RAS-RAF-MEK-ERK signaling pathway by APP and Aβ42 oligomers in a cell culture system as well as in postmortem human AD brains indicated a pathologic link between Aβ and this particular MAPK pathway [57,58,59]. It has been suggested by others that the two main pathologies of AD, amyloid and tau aggregation, affect the aging brain and cause changes in large-scale neuronal circuits . We show in the present study that DNA Aβ42 immunization led to significant changes in several pathways. Further analyses of the mechanism of action on tau reduction and changes in cellular signaling pathways in the DNA Aβ42 trimer-immunized mice are goals for future research.
It had been shown before in the 3xTg-AD mouse model that antitau immunotherapy or passive anti-Aβ immunotherapy led to removal of tau or Aβ or both [19, 43, 55, 61,62,63,64]. Of note, these studies were of passive immunotherapy using preformed mAbs or the intracranial injection of anti-Aβ or antitau antibodies, which is different from the active immunization done in the present study. It had also been shown before that immunization with a DNA vaccine encoding Aβ1–11 or a short tau epitope led to the production of antibodies against Aβ or tau, respectively [65, 66]. We show for the first time a different mechanism in which active DNA Aβ42 trimer immunization in the 3xTg-AD mouse model results in reduction of both pathologies with one vaccine: Aβ reduction due to antibodies generated against Aβ and tau reduction due to an indirect mechanism in which less Aβ led to less tau kinase activation and therefore to less tau phosphorylation. Of note, also in AN-1792, a clinical trial using Aβ42 immunotherapy in patients with AD, a trend toward reduction in cerebrospinal fluid phospho-tau concentrations was reported, and analysis of postmortem brain tissue showed a reduction of aggregated tau in neuronal processes [1,2,3, 67].
Current assessments of Aβ immunotherapy for the prevention of AD in several completed and ongoing trials show divergent responses . Positive results in patients treated with the mAb aducanumab support the effectiveness of Aβ immunotherapy in patients with early AD . Aducanumab is a fully human IgG1 antibody that corresponds to the IgG2a antibody isotype in the mouse. Of note, aducanumab has been characterized as an antibody that binds to soluble Aβ42 oligomers and insoluble Aβ42 fibrils prepared in vitro, but not Aβ42 monomers, consistent with the detection of conformational but not linear epitopes. This antibody reactivity might be similar to antibodies generated in response to immunization with DNA Aβ42 trimer as shown in the present study.
We present data showing for the first time that active immunization with a DNA plasmid coding for an Aβ trimer (3xAβ1–42) designed to induce an anti-Aβ humoral immune response in the 3xTg-AD mouse model significantly reduced both of the main AD pathologies, amyloid and tau. We show a significant reduction in activated protein levels for p44/p44 MAPK (ERK1/2), the upstream MEK, and GSK3β. Our data support significant changes in the Ras-Raf-MEK-ERK signaling pathway in AD mouse model brain due to DNA Aβ42 immunotherapy, and this is a goal of further studies. DNA Aβ42 immunization in patients with AD has the potential to modify early and late changes in this disease. It is expected that DNA Aβ42 trimer immunotherapy in a clinical trial will reduce both plaques and tangles in patients with AD.
Analysis of variance
Amyloid precursor protein
- Aβ42 :
Amyloid-β peptide 1–42
Ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid
Enzyme-linked immunosorbent assay
Extracellular signal-regulated kinase
Glyceraldehyde 3-phosphate dehydrogenase
Glycogen synthase kinase 3β
Mitogen-activated protein kinase
Mitogen-activated protein kinase kinase
Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C. Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology. 2003;61(1):46–54.
Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, Koller M, AN1792(QS-21)-201 Study. Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology. 2005;64:1563–72.
Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM, AN1792(QS-21)-201 Study Team. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2006;64:1553–62.
Blennow K, Zetterberg H, Rinne JO, Salloway S, Wei J, Black R, Grundman M, Liu E, AAB-001 201/202 Investigators. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol. 2011;69(8):1002–10.
Adolfsson O, Pihlgren M, Toni N, Varisco Y, Buccarello AL, Antoniello K, Lohmann S, Piorkowska K, Gafner V, Atwal JK, Maloney J, Chen M, Gogineni A, Weimer RM, Mortensen DL, Friesenhahn M, Ho C, Paul R, Pfeifer A, Muhs A, Watts RJ. An effector-reduced anti-β-amyloid (Aβ) antibody with unique Aβ binding properties promotes neuroprotection and glial engulfment of Aβ. J Neurosci. 2012;32(28):9677–89.
Bohrmann B, Baumann K, Benz J, Gerber F, Huber W, Knoflach F, Messer J, Oroszlan K, Rauchenberger R, Richter WF, Rothe C, Urban M, Bardroff M, Winter M, Nordstedt C, Loetscher H. Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β. J Alzheimers Dis. 2012;28(1):49–69.
Farlow M, Arnold SE, van Dyck CH, Aisen PS, Snider BJ, Porsteinsson AP, Friedrich S, Dean RA, Gonzales C, Sethuraman G, DeMattos RB, Mohs R, Paul SM, Siemers ER. Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease. Alzheimers Dement. 2012;8(4):261–71.
Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, O’Gorman J, Qian F, Arastu M, Li M, Chollate S, Brennan MS, Quintero-Monzon O, Scannevin RH, Arnold HM, Engber T, Rhodes K, Ferrero J, Hang Y, Mikulskis A, Grimm J, Hock C, Nitsch RM, Sandrock A. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature. 2016;537(7618):50–6.
Iqbal K, Liu F, Gong CX. Tau and neurodegenerative disease: the story so far. Nat Rev Neurol. 2016;1:15–27.
Novak P, Schmidt R, Kontsekova E, Zilka N, Kovacech B, Skrabana R, Vince-Kazmerova Z, Katina S, Fialova L, Prcina M, Parrak V, Dal-Bianco P, Brunner M, Staffen W, Rainer M, Ondrus M, Ropele S, Smisek M, Sivak R, Winblad B, Novak M. Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer’s disease: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Neurol. 2017;16(2):123–34.
Kontsekova E, Zilka N, Kovacech B, Novak P, Novak M. First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer’s disease model. Alzheimers Res Ther. 2014;6:44.
Levites Y, Sinyavskaya O, Rosario AM, Cruz PE, Lewis J, Golde TE. Targeting intra vs extracellular tau by recombinant antibodies [abstract]. Neurodegener Dis. 2015;15(Suppl 1):337.
Sigurdsson EM. Tau immunotherapy. Neurodegener Dis. 2016;16(1–2):34–8.
Theunis C, Crespo-Biel N, Gafner V, Pihlgren M, López-Deber MP, Reis P, Hickman DT, Adolfsson O, Chuard N, Ndao DM, Borghgraef P, Devijver H, van Leuven F, Pfeifer A, Muhs A. Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy. PLoS One. 2013;8:e72301.
Troquier L, Caillierez M, Burnouf S, Fernandez-Gomez FJ, Grosjean MJ, Zommer N, Sergeant N, Schraen-Maschke S, Blum D, Buee L. Targeting phospho-Ser422 by active Tau immunotherapy in the THY-Tau22 mouse model: a suitable therapeutic approach. Curr Alzheimer Res. 2012;9:397–405.
Congdon EE, Gu J, Sait HB, Sigurdsson EM. Antibody uptake into neurons occurs primarily via clathrin-dependent Fcγ receptor endocytosis and is a prerequisite for acute tau protein clearance. J Biol Chem. 2013;288:35452–65.
Gu J, Congdon EE, Sigurdsson EM. Two novel Tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce Tau protein pathology. J Biol Chem. 2013;288:33081–95.
Ittner A, Bertz J, Suh LS, Stevens CH, Götz J, Ittner LM. Tau-targeting passive immunization modulates aspects of pathology in tau transgenic mice. J Neurochem. 2015;132:135–45.
Walls KC, Ager RR, Vasilevko V, Cheng D, Medeiros R, LaFerla FM. p-Tau immunotherapy reduces soluble and insoluble tau in aged 3xTg-AD mice. Neurosci Lett. 2014;575:96–100.
Yanamandra K, Kfoury N, Jiang H, Mahan TE, Ma S, Maloney SE, Wozniak DF, Diamond MI, Holtzman DM. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron. 2013;80:402–14.
Kutzler MA, Weiner DB. DNA vaccines: ready for prime time? Nat Rev Genet. 2008;9(10):776–88.
Lambracht-Washington D, Qu BX, Fu M, Eagar TN, Stüve O, Rosenberg RN. DNA β-amyloid (1–42) trimer immunization for Alzheimer disease in a wild-type mouse model. JAMA. 2009;302(16):1796–802.
Lambracht-Washington D, Qu BX, Fu M, Eagar TN, Stüve O, Rosenberg RN. DNA immunization against amyloid β 42 has high potential as safe therapy for Alzheimer’s disease as it diminishes antigen specific Th1 and Th17 cell proliferation. Cell Mol Neurobiol. 2011;31:867–74.
Lambracht-Washington D, Rosenberg RN. Co-stimulation with TNF receptor superfamily 4/25 antibodies enhances in-vivo expansion of CD4+CD25+Foxp3+ T cells (Tregs) in a mouse study for active DNA Aβ42 immunotherapy. J Neuroimmunol. 2015;278:90–9.
Lambracht-Washington D, Rosenberg RN. A non-inflammatory immune response in aged DNA Aβ42 immunized mice supports its safety for possible use as immunotherapy in AD patients. Neurobiol Aging. 2015;36(3):1274–81.
Qu B-X, Xiang Q, Li L, Johnston SA, Hynan LS, Rosenberg RN. Aβ42 gene vaccine prevents Aβ42 deposition in brain of double transgenic mice. J Neurol Sci. 2007;260:204–13.
Lambracht-Washington D, Rosenberg RN. Active DNA Aβ42 vaccination as immunotherapy for Alzheimer disease. Transl Neurosci. 2012;3(4):307–13.
Rosenberg RN, Lambracht-Washington D, Yu G, Xia W. Genomics of Alzheimer disease: a review. JAMA Neurol. 2016;73(7):867–74.
Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM. Triple-transgenic model of Alzheimer’s disease with plaques and tangles: intracellular Aβ and synaptic dysfunction. Neuron. 2003;39(3):409–21.
Oddo S, Caccamo A, Kitazawa M, Tseng BP, LaFerla FM. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer’s disease. Neurobiol Aging. 2003;24(8):1063–70.
Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 2010;8(6):e1000412.
Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9(7):671–5.
Grant SM, Ducatenzeiler A, Szyf M, Cuello AC. Aβ immunoreactive material is present in several intracellular compartments in transfected, neuronally differentiated, P19 cells expressing the human amyloid β-protein precursor. J Alzheimers Dis. 2000;2(3–4):207–22.
Iulita MF, Allard S, Richter L, Munter LM, Ducatenzeiler A, Weise C, Do Carmo S, Klein WL, Multhaup G, Cuello AC. Intracellular Aβ pathology and early cognitive impairments in a transgenic rat overexpressing human amyloid precursor protein: a multidimensional study. Acta Neuropathol Commun. 2014;2:61.
Augustinack JC, Schneider A, Mandelkow EM, Hyman BT. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer’s disease. Acta Neuropathol. 2002;103(1):26–35.
Sahara N, DeTure M, Ren Y, Ebrahim AS, Kang D, Knight J, Volbracht C, Pedersen JT, Dickson DW, Yen SH, Lewis J. Characteristics of TBS-extractable hyperphosphorylated tau species: aggregation intermediates in rTg4510 mouse brain. J Alzheimers Dis. 2013;33(1):249–63.
Qu BX, Lambracht-Washington D, Fu M, Eagar TN, Stüve O, Rosenberg RN. Analysis of three plasmid systems for use in DNA Aβ42 immunization as therapy for Alzheimer’s disease. Vaccine. 2010;28:5280–7.
Lambracht-Washington D, Rosenberg RN. DNA Aβ42 immunization generates a multivalent vaccine: antibodies in plasma of active full-length DNA Aβ42 immunized mice show polyclonal Aβ42 peptide binding [abstract]. Alzheimers Dement. 2015;11(7 Suppl):P842.
Lambracht-Washington D, Fu M, Wight-Carter M, Riegel M, Rosenberg RN. Evaluation of a DNA Aβ42 vaccine in aged NZW rabbits: antibody kinetics and immune profile after intradermal immunization with full-length DNA Aβ42 trimer. J Alzheimers Dis. 2017;57(1):97–112.
Lambracht-Washington D, Fu M, Frost P, Rosenberg RN. Evaluation of a DNA Aβ42 vaccine in adult rhesus monkeys (Macaca mulatta): antibody kinetics and immune profile after intradermal immunization with full-length DNA Aβ42 trimer. Alzheimers Res Ther. 2017;9(1):30.
Chong YH, Shin YJ, Lee EO, Kayed R, Glabe CG, Tenner AJ. ERK1/2 activation mediates Aβ oligomer-induced neurotoxicity via caspase-3 activation and tau cleavage in rat organotypic hippocampal slice cultures. J Biol Chem. 2006;281(29):20315–25.
Guillozet-Bongaarts AL, Cahill ME, Cryns VL, Reynolds MR, Berry RW, Binder LI. Pseudophosphorylation of tau at serine 422 inhibits caspase cleavage: in vitro evidence and implications for tangle formation in vivo. J Neurochem. 2006;97(4):1005–14.
Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Aβ immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron. 2004;43(3):321–32.
Oddo S, Caccamo A, Tran L, Lambert MP, Glabe CG, Klein WL, LaFerla FM. Temporal profile of amyloid-β (Aβ) oligomerization in an in vivo model of Alzheimer disease: a link between Aβ and tau pathology. J Biol Chem. 2006;281(3):1599–604.
Rissman RA, Poon WW, Blurton-Jones M, Oddo S, Torp R, Vitek MP, LaFerla FM, Rohn TT, Cotman CW. Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J Clin Invest. 2004;114(1):121–30.
Cho JH, Johnson GV. Glycogen synthase kinase 3β induces caspase-cleaved tau aggregation in situ. J Biol Chem. 2004;279(52):54716–23.
Gamblin TC, Chen F, Zambrano A, Abraha A, Lagalwar S, Guillozet AL, Lu M, Fu Y, Garcia-Sierra F, LaPointe N, Miller R, Berry RW, Binder LI, Cryns VL. Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer’s disease. Proc Natl Acad Sci U S A. 2003;100(17):10032–7.
Delobel P, Lavenir I, Fraser G, Ingram E, Holzer M, Ghetti B, Spillantini MG, Crowther RA, Goedert M. Analysis of tau phosphorylation and truncation in a mouse model of human tauopathy. Am J Pathol. 2008;172(1):123–31.
Mead E, Kestoras D, Gibson Y, Hamilton L, Goodson R, Jones S, Eversden S, Davies P, O’Neill M, Hutton M, Szekeres P, Wolak J. Halting of caspase activity protects tau from MC1-conformational change and aggregation. J Alzheimers Dis. 2016;54(4):1521–38.
Lambracht-Washington D, Qu BX, Fu M, Anderson LD Jr, Eagar TN, Stüve O, Rosenberg RN. A peptide prime-DNA boost immunization protocol provides significant benefits as a new generation Aβ42 DNA vaccine for Alzheimer disease. J Neuroimmunol. 2013;254(1–2):63–8.
Nimmerjahn F, Ravetch JV. Divergent immunoglobulin G subclass activity through selective Fc receptor binding. Science. 2005;310(5753):1510–2.
Huber VC, McKeon RM, Brackin MN, Miller LA, Keating R, Brown SA, Makarova N, Perez DR, Macdonald GH, McCullers JA. Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza. Clin Vaccine Immunol. 2006;13(9):981–90.
Beers SA, Glennie MJ, White AL. Influence of immunoglobulin isotype on therapeutic antibody function. Blood. 2016;127(9):1097–101.
Zago W, Buttini M, Comery TA, Nishioka C, Gardai SJ, Seubert P, Games D, Bard F, Schenk D, Kinney GG. Neutralization of soluble, synaptotoxic amyloid β species by antibodies is epitope specific. J Neurosci. 2012;32(8):2696–702.
Rasool S, Martinez-Coria H, Wu JW, LaFerla F, Glabe CG. Systemic vaccination with anti-oligomeric monoclonal antibodies improves cognitive function by reducing Aβ deposition and tau pathology in 3xTg-AD mice. J Neurochem. 2013;126(4):473–82.
Kirouac L, Rajic AJ, Cribbs DH, Padmanabhan J. Activation of Ras-ERK signaling and GSK-3 by amyloid precursor protein and amyloid Β Facilitates neurodegeneration in Alzheimer’s disease. eNeuro. 2017;4(2):e0149–16.201.
Kim EK, Choi EJ. Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta. 2010;1802(4):396–405.
Ferrer I, Blanco R, Carmona M, Puig B. Phosphorylated mitogen-activated protein kinase (MAPK/ERK-P), protein kinase of 38 kDa (p38-P), stress-activated protein kinase (SAPK/JNK-P), and calcium/calmodulin-dependent kinase II (CaM kinase II) are differentially expressed in tau deposits in neurons and glial cells in tauopathies. J Neural Transm (Vienna). 2001;108(12):1397–415.
Qi H, Prabakaran S, Cantrelle FX, Chambraud B, Gunawardena J, Lippens G, Landrieu I. Characterization of neuronal tau protein as a target of extracellular signal-regulated kinase. J Biol Chem. 2016;291(14):7742–53.
Sepulcre J, Sabuncu MR, Li Q, El Fakhri G, Sperling R, Johnson KA. Tau and amyloid-β proteins distinctively associate to functional network changes in the aging brain. Alzheimers Dement. 2017;13(11):1261–9.
Dai CL, Tung YC, Liu F, Gong CX, Iqbal K. Tau passive immunization inhibits not only tau but also Aβ pathology. Alzheimers Res Ther. 2017;9(1):1.
Oddo S, Vasilevko V, Caccamo A, Kitazawa M, Cribbs DH, LaFerla FM. Reduction of soluble Aβ and tau, but not soluble Aβ alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J Biol Chem. 2006;281(51):39413–23.
Lathuilière A, Laversenne V, Astolfo A, Kopetzki E, Jacobsen H, Stampanoni M, Bohrmann B, Schneider BL, Aebischer P. A subcutaneous cellular implant for passive immunization against amyloid-β reduces brain amyloid and tau pathologies. Brain. 2016;139(Pt 5):1587–604.
Castillo-Carranza DL, Guerrero-Muñoz MJ, Sengupta U, et al. Tau immunotherapy modulates both pathological tau and upstream amyloid pathology in an Alzheimer’s disease mouse model. J Neurosci. 2015;35(12):4857–68.
Movsesyan N, Ghochikyan A, Mkrtichyan M, Petrushina I, Davtyan H, Olkhanud PB, Head E, Biragyn A, Cribbs DH, Agadjanyan MG. Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy. PLoS One. 2008;3(5):e2124.
Davtyan H, Zagorski K, Rajapaksha H, Hovakimyan A, Davtyan A, Petrushina I, Kazarian K, Cribbs DH, Petrovsky N, Agadjanyan MG, Ghochikyan A. Alzheimer’s disease Advax(CpG)-adjuvanted MultiTEP-based dual and single vaccines induce high-titer antibodies against various forms of tau and Aβ pathological molecules. Sci Rep. 2016;6:28912.
Boche D, Donald J, Love S, et al. Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Aβ42 immunization in Alzheimer’s disease. Acta Neuropathol. 2010;120(1):13–20.
Abbott A, Dolgin E. News in focus: leading Alzheimer’s theory survives drug failure. Nature. 2016;540:15–6.
We thank the UTSW Whole Brain Microscopy Facility (WBMF) in the Department of Neurology and Neurotherapeutics for assistance with slide scanning. WBMF is supported by the Texas Institute for Brain Injury and Repair (TIBIR).
The research reported in this publication was supported by National Institute on Aging/National Institutes of Health (NIH) grant P30AG12300-21; the Zale Foundation; the Rudman Foundation; Presbyterian Village North Foundation; Freiberger, Losinger, and Denker Family Funds; “Triumph over Alzheimer’s” Charity; AWARE; the National Center for Advancing Translational Sciences of the NIH under Center for Translational Medicine award number UL 1TR001105; and a grant from the Friends of the Alzheimer’s Disease Center.
Availability of data and materials
Animal use for this study was approved by the Institutional Animal Care and Use Committee at UTSW.
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.